U.S. Reaches Deal for Nearly 600 Million Doses of COVID-19 Vaccine

Medical News
>
Critical Care
>
U.S. Reaches Deal for Nearly 600 Million Doses of COVID-19 Vaccine

modernClinician Editorial Team Posted July 22nd

Large-scale safety trials scheduled to start this month; regulatory review could occur as early as October

WEDNESDAY, July 22, 2020 (HealthDay News) — A nearly $2 billion contract with pharmaceutical company Pfizer and a German biotechnology firm will provide the United States with up to 600 million doses of a COVID-19 vaccine being developed by the companies, the U.S. government says.

Large-scale safety trials of the vaccine are scheduled to start this month and a regulatory review could occur as early as October, according to The New York Times.

Under the deal, the U.S. government would receive the first 100 million doses of the vaccine for $1.95 billion, with the rights to obtain up to 500 million more. The vaccine would be free to Americans.

Before it could be distributed, the vaccine would have to receive at least emergency approval by the U.S. Food and Drug Administration, The Times reported.

The New York Times Article